Syros Pursues Combination Development for Lead Candidate after Phase II Miss

Syros Pharmaceuticals said it will pursue development of its lead candidate SY-1425 (tamibarotene) in a combination therapy after acknowledging that only one of 48 evaluable patients achieved complete response to the treatment alone in an ongoing Phase II trial.The results—presented during the 59 th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta—disappointed investors, touching off a selloff that sent the price of Syros shares falling about 50% in prema